Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexpanthenol enemas in ulcerative colitis: a pilot study

E V Loftus1, W J Tremaine, R A Nelson

  • 1Division of Gastroenterology and Internal Medicine, Mayo Clinic Rochester, MN 55905, USA.

Mayo Clinic Proceedings
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.

Digestive diseases and sciences·2024
Same author

Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.

Alimentary pharmacology & therapeutics·2018
Same author

Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2018
Same author

Disparities in survival after trimodality therapy for esophageal adenocarcinoma.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2018
Same author

Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.

Alimentary pharmacology & therapeutics·2017
Same author

Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.

Alimentary pharmacology & therapeutics·2017

Topical dexpanthenol (pantothenic acid precursor) enemas did not improve ulcerative colitis symptoms or colonic coenzyme A levels in a pilot study. Absorption occurred, but therapeutic effects were not observed at the tested dosage.

Area of Science:

  • Gastroenterology
  • Metabolic Biochemistry

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Pantothenic acid (PA), a precursor to coenzyme A (CoA), plays a role in fatty acid metabolism.
  • Altered fatty acid metabolism has been implicated in UC pathogenesis.

Purpose of the Study:

  • To investigate if topical dexpanthenol administration increases colonic CoA levels and improves fatty acid oxidation in UC patients.
  • To assess the therapeutic potential of dexpanthenol enemas for active left-sided ulcerative colitis.

Main Methods:

  • An open-label pilot study involving three patients with active left-sided UC.
  • Nightly enemas containing 1,000 mg dexpanthenol for 4 weeks.
  • Measurements included urinary PA and dicarboxylic acids, fecal short-chain fatty acids, colonic CoA activity, and clinical/histologic disease activity indices.

Related Experiment Videos

Main Results:

  • Urinary PA levels increased, indicating dexpanthenol absorption.
  • No significant changes were observed in colonic CoA concentrations, fecal short-chain fatty acids, or urinary dicarboxylic acids.
  • Clinical and histologic disease activity indices showed no improvement; abdominal cramping increased in all patients.

Conclusions:

  • Topical dexpanthenol is absorbed but does not enhance colonic CoA activity or improve disease markers in active ulcerative colitis at the tested dose.
  • Further research with different dosages or formulations may be warranted, but this study did not support dexpanthenol as a treatment for UC.